The Effect of Beta-blockers in Substance P Levels and the Swallowing Function (BETASP)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Marta Miarons
- Phone Number: 0034600297227
- Email: mmiarons@csdm.cat
Study Contact Backup
- Name: Laia Rofes
Study Locations
-
-
Barcelona
-
Mataró, Barcelona, Spain, 08304
- Recruiting
- Mataro Hospital
-
Contact:
- Marta Miarons
- Phone Number: 0034600297227
- Email: mmiarons@csdm.cat
-
Contact:
- Laia Rofes
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients taking and not taking beta-blockers
Exclusion Criteria:
- Participants with heat and neck or esophageal cancer
- Participants with stroke or neurological disease
- Participants with central nervous system disease
- Participants with concomitant treatment with Angiotensin converting enzyme inhibitors (ACEI), Angiotensin II receptor antagonists (ARA-II), Antipsychotics, Dopamine agonists, Capsaicine.
- Participants with severe clinical signs of aspiration, including oxygen desaturation ≥3%.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
BETA-BLOCKERS
Patients taking beta-blockers with or without dysphagia
|
An overall assessment is going to be carry out by a multidisciplinary team during the visit. Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire [4]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present. All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)
Other Names:
|
|
NO BETA-BLOCKERS
Patients not taking beta-blockers with or without dysphagia
|
An overall assessment is going to be carry out by a multidisciplinary team during the visit. Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire [4]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present. All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Substance P levels
Time Frame: 1 year
|
In blood and saliva
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marta Miarons, Mataro Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2017/05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Swallowing Disorder
-
NCT06411236Not yet recruitingDysphagia | Swallowing Disorder | Swallowing Substances
-
NCT07455279Not yet recruitingSwallowing Function | Normal Pediatric Swallowing Physiology | Swallowing Muscle Activation Patterns in Children
-
NCT03163355CompletedSwallowing Disorder
-
NCT05579041Completed
-
NCT04658316Completed
-
NCT03831789CompletedDysphagia | Swallowing Disorder
-
NCT04591665CompletedSwallowing Disorder
-
NCT04040803CompletedDysphagia | Swallowing Disorder
Clinical Trials on Dysphagia
-
NCT07005427Active, not recruiting
-
NCT06006195Not yet recruitingSwallowing Contraction Strength
-
NCT01974089CompletedPneumonia | Dysphagia
-
NCT07549724Recruiting
-
NCT00288834CompletedStroke | Dysphagia | Cerebrovascular Accident
-
NCT05063708CompletedMultiple Sclerosis | Deglutition Disorders
-
NCT03387267TerminatedStroke | Multiple Sclerosis | Parkinson Disease | Dementia | Alzheimer Disease | Oropharyngeal Dysphagia
-
NCT04739514Unknown